Oramed Pharmaceuticals Inc. Logo

Oramed Pharmaceuticals Inc.

Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.

ORMP | TA

Overview

Corporate Details

ISIN(s):
US68403P2039
LEI:
Country:
Israel
Address:
20 Mamilla Avenue, 9414904 Jerusalem
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company specializing in the development of oral drug delivery systems. Established in 2006, the company leverages its proprietary platform technology to transform injectable drugs into oral therapies, aiming to enhance patient comfort, compliance, and safety. Its flagship product is an oral insulin capsule for the treatment of type 2 diabetes, which has undergone extensive clinical development. Oramed's primary focus is on providing non-invasive alternatives to injected medications, particularly for chronic conditions like diabetes.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-22 09:42
Post-Annual General Meeting Information
Other Report or Announcement
English 118.7 KB
2025-08-22 09:42
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-08-22 09:41
Registration Form
Other Report or Announcement
English 181.3 KB
2025-08-22 09:41
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-08-17 15:18
Foreign Filer Report
FORM 10-Q- FINANCIAL STATEMENTS AS OF JUNE 30, 2025
English 36.4 KB
2025-08-17 15:16
Major Shareholding Notification
Form 13G
English 93.7 KB
2025-08-17 15:16
Foreign Filer Report
Form 13G
English 36.4 KB
2025-07-23 17:53
Delisting Announcement
Option Agreement for the Repurchase of Warrants
English 316.7 KB
2025-07-23 17:53
Foreign Filer Report
Option Agreement for the Repurchase of Warrants
English 36.4 KB
2025-07-18 14:52
Proxy Solicitation & Information Statement
Other Report or Announcement
English 1.4 MB
2025-07-18 14:52
Proxy Solicitation & Information Statement
Other Report or Announcement
English 36.4 KB
2025-07-18 14:51
Registration Form
Other Report or Announcement
English 448.1 KB
2025-07-18 14:51
Registration Form
Other Report or Announcement
English 36.4 KB
2025-07-18 14:50
Annual / Quarterly Financial Statement
Other Report or Announcement
English 359.9 KB
2025-07-18 14:50
Foreign Filer Report
Other Report or Announcement
English 36.4 KB

Automate Your Workflow. Get a real-time feed of all Oramed Pharmaceuticals Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Oramed Pharmaceuticals Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Oramed Pharmaceuticals Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.